Missing and unerupted teeth in osteogenesis imperfecta.

Agenesis Bisphosphonate Missing teeth Osteogenesis imperfecta Rare disease Retained teeth Tooth development Tooth eruption Unerupted

Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
09 2021
Historique:
received: 14 01 2021
revised: 02 05 2021
accepted: 14 05 2021
pubmed: 22 5 2021
medline: 1 7 2021
entrez: 21 5 2021
Statut: ppublish

Résumé

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bone fragility and craniofacial and dental abnormalities such as congenitally missing teeth and teeth that failed to erupt which are believed to be doubled in OI patients than normal populations and were associated with low oral health quality of life. However, the etiology of these abnormalities remains unclear. To understand the factors influencing missing and unerupted teeth, we investigated their prevalence in a cohort of OI patients as a function of the clinical phenotype (OI type), the genetic variant type, the tooth type and the onset of bisphosphonate treatment. A total of 144 OI patients were recruited from The Shriners Hospital, Montreal, Canada, between 2016 and 2017. Patients were evaluated using intraoral photographs and panoramic radiographs. Missing teeth were evaluated in all patients, and unerupted teeth were assessed only in patients ≥15 years old (n = 82). On average, each OI patient had 2.4 missing teeth and 0.8 unerupted teeth, and the most common missing and unerupted teeth were the premolars and the upper second molars, respectively. These phenomena were more prominent in OI type III and IV than in OI type I, and were not sex or age-related. Missing teeth were significantly more common in patients with C-propeptide variants than all other variants (p-value <0.05). Unerupted teeth were significantly more common in patients with α1 and α2 glycine variants or substitutions than in those with haploinsufficiency variants. Early-onset of bisphosphonate treatment would significantly increase the risk of unerupted teeth in patients with OI types III and IV (OR = 1.68, 95% CI (1.15-1.53)). The prevalence of missing and unerupted teeth at the tooth type level in OI patients varies according to the nature of the collagen variants and the OI type. These findings highlight the role of collagen in tooth development and eruption.

Identifiants

pubmed: 34020077
pii: S8756-3282(21)00173-3
doi: 10.1016/j.bone.2021.116011
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

116011

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Doaa Taqi (D)

Faculty of Dentistry, McGill University, Montreal, Quebec, Canada. Electronic address: doaa.taqi@mail.mcgill.ca.

Hanan Moussa (H)

Faculty of Dentistry, McGill University, Montreal, Quebec, Canada; Faculty of Dentistry, Benghazi university, Libya. Electronic address: hanan.moussa@mail.mcgill.ca.

Timothy Schwinghamer (T)

Faculty of Dentistry, McGill University, Montreal, Quebec, Canada. Electronic address: timothy.schwinghamer@mail.mcgill.ca.

Alexandre Rezende Vieira (AR)

Department of Oral Biology, School of Dental Medicine, University of Pittsburgh, USA. Electronic address: arv11@pitt.edu.

Didem Dagdeviren (D)

Faculty of Dentistry, McGill University, Montreal, Quebec, Canada. Electronic address: didem.dagdeviren@mcgill.ca.

Jean-Marc Retrouvey (JM)

Faculty of Dentistry, McGill University, Montreal, Quebec, Canada; School of Dentistry, University of Missouri, Kansas City, USA. Electronic address: jean-marc.retrouvey@mcgill.ca.

Frank Rauch (F)

Shriners Hospital for Children, Montreal, Quebec, Canada. Electronic address: frank.rauch@mcgill.ca.

Faleh Tamimi (F)

Faculty of Dentistry, McGill University, Montreal, Quebec, Canada; College of Dental Medicine, QU Health, Qatar University, Doha, Qatar. Electronic address: faleh.tamimimarino@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH